Genzyme Corp.

500 Kendall Street,
Cambridge, Massachusetts 02142
United States,
(617) 252-7500
www.genzyme.com

Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.

M&A Summary

Buy vs Sell

Year ≤ '12 '13 '14 '15 '16 '17 T
Buy (0.2/yr) # 11 - - 1 - - 12
vol $4.4B $4.4B
Sell (0.0/yr) # 3 - - - - - 3
vol $1.2B $1.2B
  15

Top M&A Advisors

Financial Deals
Sign-up to View
1
Sign-up to View
1
Legal Deals
Sign-up to View
1

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest ILEX Oncology, Inc.
$1.0B (2004-12-21)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest Genzyme Genetics
$925M (2010-12-01)

Genzyme was acquired by Sanofi SA on February 16, 2011.

Genzyme has acquired 16 companies of its own, including 1 in the last 5 years. A total of 8 acquisitions came from private equity firms. It has also divested 3 assets.

Genzyme’s largest acquisition to date was in 2004, when it acquired ILEX Oncology for $1.0B. It’s largest disclosed sale occurred in 2010, when it sold Genzyme Genetics to Laboratory of America Holdings for $925M. Genzyme has acquired in 8 different US states, and 4 countries. The Company’s most targeted sectors include life science (75%) and medical products (25%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 414 life science companies that have made at least 1 acquisition, 25 have acquired at least 5 companies, and 3 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 25 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.

Join Mergr and gain access to Genzyme’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.


What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.3K Private Equity Firms
  • 112K M&A Transactions
  • 121K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 38K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.